Literature DB >> 19912087

Variability in the rate of prescription and cost of domiciliary oxygen therapy in Australia.

John G Serginson1, Ian A Yang, John G Armstrong, David M Cooper, Anthony M Matthiesson, Stephen C Morrison, Judy M Gair, Barbara Cooper, Paul V Zimmerman.   

Abstract

OBJECTIVES: To determine the rate of prescription of and government expenditure for domiciliary oxygen therapy (DOT) in Australia, and to identify interstate differences in rates, costs and service provision.
DESIGN: Retrospective observational study. PARTICIPANTS AND
SETTING: Government departments and health services (state and federal) that funded DOT in Australia in the 2004-05 financial year (including the Department of Veterans' Affairs [DVA] and the Department of Health and Ageing [DoHA]). MAIN OUTCOME MEASURES: Prescription rates, cost of DOT in 2004-05, and services provided in each jurisdiction.
RESULTS: In 2005, 20,127 patients were using DOT, giving a national prevalence of 100 prescriptions per 100,000 population. The total cost was about $31 million. State governments, the DVA and the DoHA funded 13,899 (69%), 4084 (20%) and 2144 (11%) patients, respectively. Prescription rates varied threefold between the states, ranging from 44 (Northern Territory) to 133 (Tasmania) per 100,000 population. Cost per patient per year varied fourfold between the DVA and the DoHA. All jurisdictions funded oxygen according to the clinical criteria of the Thoracic Society of Australia and New Zealand, but considerable variability in service provision was identified.
CONCLUSION: DOT prescription rates and costs vary considerably between jurisdictions. An urgently needed national DOT register would enable the current variability to be understood and allow service planning and benchmarking of clinical outcomes.

Entities:  

Mesh:

Year:  2009        PMID: 19912087

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  5 in total

1.  Burn injury associated with home oxygen use in patients with chronic obstructive pulmonary disease.

Authors:  Gulshan Sharma; Ragai Meena; James S Goodwin; Wei Zhang; Yong-Fang Kuo; Alexander G Duarte
Journal:  Mayo Clin Proc       Date:  2015-04       Impact factor: 7.616

2.  Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data.

Authors:  Yuanyuan Gu; Sonia García-Pérez; John Massie; Kees van Gool
Journal:  Eur J Health Econ       Date:  2014-08-09

3.  Why are some evidence-based care recommendations in chronic obstructive pulmonary disease better implemented than others? Perspectives of medical practitioners.

Authors:  Kylie N Johnston; Mary Young; Karen A Grimmer-Somers; Ral Antic; Peter A Frith
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-12-06

Review 4.  Home oxygen therapy.

Authors:  Christine F McDonald
Journal:  Aust Prescr       Date:  2022-02-01

Review 5.  Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns.

Authors:  Yet H Khor; Elisabetta A Renzoni; Dina Visca; Christine F McDonald; Nicole S L Goh
Journal:  ERJ Open Res       Date:  2019-09-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.